Long noncoding RNA-ATB promotes cell proliferation, migration and invasion in gastric cancer

YING CHEN1*, GUOQING WEI2*, HONGWEI XIA2, QIULIN TANG2 and FENG BI1,2

1Department of Medical Oncology, West China Hospital, Sichuan University; 2Laboratory of Signal Transduction and Molecular Targeted Therapy, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan 610041, P.R. China

Received December 31, 2016; Accepted August 8, 2017

DOI: 10.3892/mmr.2017.8077

Abstract. Long noncoding RNA (lncRNA)-activated by transforming growth factor (TGF)-β (lncRNA-ATB) was recognized as an unfavorable prognostic factor in various cancers; however, its regulatory role in gastric cancer (GC) remains elusive. The present study aimed to measure lncRNA-ATB expression in GC and to explore its involvement in GC progression. lncRNA-ATB expression levels were measured in 40 pairs of GC tissues and their normal adjacent tissues, as well as in 5 GC cell lines and a normal gastric mucosal cell line by reverse transcription-quantitative polymerase chain reaction. Knockdown experiments were performed to explore the effect of lncRNA-ATB on the cell proliferation, invasion and migration. The results demonstrated that lncRNA-ATB expression levels in GC tissues and GC cell lines were significantly higher than in the adjacent normal tissues and normal gastric mucosal cells. Further analysis of the correlation between the clinicopathological features and lncRNA-ATB expression indicated that higher expression of lncRNA-ATB was correlated with increased invasion depth, more distant metastasis and advanced tumor-node-metastasis stage. In addition, downregulated lncRNA-ATB expression suppressed cellular proliferation, invasion and migration of GC cells. In conclusion, these data suggested that lncRNA-ATB may serve as a clinical outcome predictor and potential therapeutic target in GC.

Introduction

Gastric cancer (GC) is the fifth most common cancer and the third most common cause of cancer-related mortality worldwide (1). As GC development is a multistep carcinogenic process that involves numerous genetic and epigenetic alterations, a better understanding of oncogenes and tumor suppressor genes may provide additional clues for understanding the underlying molecular mechanism for GC development and for molecular targeted drug screening (2).

Long noncoding RNAs (lncRNAs) are a class of non-protein-coding transcripts that are >200 nucleotides in length (3). A number of studies have demonstrated the vital role of lncRNA expression dysregulation in numerous diseases, particularly in cancer, owing to its extensive biological functions in a wide variety of physiological and pathological processes (4,5). lncRNA-activated by transforming growth factor (TGF)-β (lncRNA-ATB), was identified during a screen of lncRNAs that are regulated by TGF-β in hepatocellular carcinoma (HCC); the study indicated that the lncRNA-ATB was upregulated in HCC (6). In addition, lncRNA-ATB was demonstrated to promote epithelial-to-mesenchymal transition (EMT) and induce the invasion-metastasis cascade through the TGF-β/microRNA (miR)-200s/zinc-finger E-box-binding homebox (ZEB) axis, which contributes to HCC progression (6). A series of subsequent studies demonstrated that upregulated lncRNA-ATB expression was correlated with poor prognosis in several cancer types, including GC (7), renal cell carcinoma (8), colorectal cancer (9) and breast cancer (10). However, the role of lncRNA-ATB in EMT process and invasion-metastasis cascade in GC remains unknown.

The present study investigated the expression of lncRNA-ATB in GC tissues and cell lines, as well as its relationship with clinicopathological features of patients with GC, with a focus on the specific modulatory roles of lncRNA-ATB in the proliferation, invasion and migration of GC cells.

Materials and methods

Specimens and relative clinical data. A total of 40 pairs of GC tissues and adjacent non-tumor tissues, along with the patients’ clinical data were obtained from the Tissue Bank in West China Hospital, Sichuan University (Chengdu, China). All tissues were stored in liquid nitrogen until used for RNA extraction. This study was approved by the Research Ethics Committee of West China Hospital, and written informed consent was received from all patients prior to enrollment in the present study.
Cell culture. Five human GC cell lines (MGC-803, MKN-45, BGC-823, MKN-28 and SGC-7901) and a normal gastric mucosal cell line (GES-1) were acquired from our laboratory depository, originally obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). All cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) and incubated in a humid atmosphere of 5% CO₂ at 37°C. The medium was replaced every 2 days.

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. The NucleoZOL Reagent (Machery-Nagel GmbH, Düren, Germany) was used to extract total RNA from the cell lines (10⁶ cells/ml) and patient tissue specimens (100 mg tissue/ml). The concentration and purity of RNA were detected using a NanoDrop 2000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc., Wilmington, DE, USA). Reverse transcription of total RNA into cDNA was performed by PrimeScript RT Reagent kit with gDNA Eraser ( Takara Bio, Inc., Otsu, Japan), following the manufacturer’s instructions.

Cell proliferation assay. Cell proliferation was examined by CCK-8 incorporation assay. Briefly, MGC-803 and MKN-45 cells were seeded in a 96-well plate (1x10⁴ cells/well) 24 h prior to transfection with 100 nM si-lncRNA-ATB or si-NC using Lipofectamine 2000. Following 48 h incubation at 37°C, CCK-8 (100 µl; 50 µM) was added into each well and incubated for 2 h at 37°C. The optical density (OD) at 450 nm was assessed using a microplate reader (Bio-Rad Laboratories, Inc.). Experiments were repeated at least three times.

Ethynyl-2-deoxyuridine (EdU) incorporation assay. Cell proliferation was also examined by EdU incorporation assay using the Cell-Light Apollo Stain kit (Guangzhou RiboBio Co., Ltd., Guangzhou, China), according to the manufacturer’s instructions. MGC-803 and MKN-45 were seeded in a 96-well plate (1x10⁴ cells/well) 24 h prior to transfection with 100 nM si-lncRNA-ATB or si-NC using Lipofectamine 2000. Following 48 h incubation at 37°C, EdU (100 µl; 50 µM) was added into each well and incubated for 2 h at 37°C. The cells were fixed in 4% paraformaldehyde in PBS (100 µl) for 20 min at room temperature. Subsequently, the cells were incubated in permeabilization solution (50 µl; 2 mg/ml) for 5 min, followed by washes with PBS. Cells were permeabilized with 1% Triton X-100 and incubated with 1X Apollo Solution for 45 min at room temperature. Hoechst solution (20 µl) was added into each well and incubated for an additional 10 min at room temperature in dark, followed by washes with PBS. Plates were observed and imaged using a Nikon Eclipse TE2000-U fluorescence microscope (Nikon Corporation, Tokyo, Japan); magnification, x20. The excitation and emission parameters of Apollo are 545 and 565 nm, respectively. The excitation and emission parameters of Hoechst are 350 and 461 nm, respectively. Experiments were repeated at least three times.

Transwell invasion and migration assays. MGC-803 and MKN-45 cells were seeded in a 6-well plate (0.5x10⁶ cells/well) and transfected with 100 nM si-lncRNA-ATB or si-NC using Lipofectamine 2000 according to the manufacturer’s instructions. Following 48 h incubation at 37°C, the transfected cells were resuspended in serum-free DMEM and added into the upper Transwell chamber with a Matrigel coated membrane. For the migration assay, cells were seeded into the upper chamber without Matrigel. The bottom chamber was filled with 400 µl DMEM containing 20% FBS. Cells were incubated for 48 h at 37°C. Non-invasive cells were washed off the upper surface with a wet cotton swab, and the cells that passed to the lower surface were fixed in 4% paraformaldehyde at room temperature for 20 min and then stained with 0.5% crystal violet solution at room temperature overnight. Images of the invaded cells were captured using an Eclipse Ti-S1 SM inverted microscope (Nikon Corporation) at x10 magnification. Experiments were repeated at least three times.

Wound-healing assay. The migratory ability of GC cells was examined by wound-healing assay. At 48 h post-siRNA transfection, MGC-803 and MKN-45 were seeded in a 6-well plate (0.5x10⁶ cells/well). The cells were allowed to reach 90% confluence, after which a scratch was made through the center of each well using the 200 µl sterile pipette tip. The scratch was observed and imaged at 0, 24 and 48 h following the scratch using an Eclipse Ti-S1 SM inverted microscope (Nikon Corporation) with x10 magnification. Experiments were repeated at least three times.

RNA interference. The lncRNA-ATB-targeted small interfering (si)RNA and a non-specific negative control (si-NC) were purchased from Shanghai GenePharma Co., Ltd. (Shanghai, China). The sequence of the si-lncRNA-ATB forward, 5'-CCA UGA GGA GUA CUG CCA ATT-3' and reverse, 5'-ATC TCT TGG GTGCTGTGAAGG-3'; internal housekeeping gene GAPDH (forward, 5'-TTG GTA TCG TGG AAG GAC TCA-3' and reverse, 5'-TGC TGG TGA AGG-3'); internal housekeeping gene GAPDH (forward, 5'-CCAUGAGGAGCUCCCAATT-3'; reverse, 5'-CACAGAAGAGGAACAATCA-3'). Relative expression levels of lncRNA-ATB were calculated by the 2⁻ΔΔCt method, normalized to GAPDH (11). The ratio of each sample was subsequently determined as the ratio of expression between GC and normal tissue from the same patient. Each experiment was performed in triplicate.

RNA interference. The lncRNA-ATB-targeted small interfering (si)RNA and a non-specific negative control (si-NC) were purchased from Shanghai GenePharma Co., Ltd. (Shanghai, China). The sequence of the si-lncRNA-ATB was: 5'-CCAUGAGGAGCUCCCAATT-3'. MGC-803 and MKN-45 cells were seeded in a 6-well plate (1x10⁴ cells/well) and then transfected with 100 nM si-lncRNA-ATB or si-NC using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc., Wilmington, DE, USA) according to the manufacturer’s instructions. Following 48 h incubation at 37°C, the transfected cells were harvested for further analysis.

Cell proliferation assay. Cell proliferation was examined by Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Inc., Shanghai, China), following the manufacturer’s instructions. Briefly, MGC-803 and MKN-45 cells were seeded in a 96-well plate (1x10⁴ cells/well) 24 h prior to transfection with 100 nM si-lncRNA-ATB or si-NC using Lipofectamine 2000. Following 48 h of transfection at 37°C, serum free DMEM (100 µl) containing 10% CCK-8 reagent was added to each well and cultured for 1 h at 37°C. The absorbance at a wavelength of 450 nm was assessed with a microplate reader (Bio-Rad Laboratories, Inc.). Experiments were repeated at least three times.

Ethynyl-2-deoxyuridine (EdU) incorporation assay. Cell proliferation was also examined by EdU incorporation assay using the Cell-Light Apollo Stain kit (Guangzhou RiboBio Co., Ltd., Guangzhou, China), according to the manufacturer’s instructions. MGC-803 and MKN-45 were seeded in a 96-well plate (1x10⁴ cells/well) 24 h prior to transfection with 100 nM si-lncRNA-ATB or si-NC using Lipofectamine 2000. Following 48 h incubation at 37°C, EdU (100 µl; 50 µM) was added into each well and incubated for 2 h at 37°C. The cells were fixed in 4% paraformaldehyde in PBS (100 µl) for 20 min at room temperature. Subsequently, the cells were incubated in permeabilization solution (50 µl; 2 mg/ml) for 5 min, followed by washes with PBS. Cells were permeabilized with 1% Triton X-100 and incubated with 1X Apollo Solution for 45 min at room temperature. Hoechst solution (20 µl) was added into each well and incubated for an additional 10 min at room temperature in dark, followed by washes with PBS. Plates were observed and imaged using a Nikon Eclipse TE2000-U fluorescence microscope (Nikon Corporation, Tokyo, Japan); magnification, x20. The excitation and emission parameters of Apollo are 545 and 565 nm, respectively. The excitation and emission parameters of Hoechst are 350 and 461 nm, respectively. Experiments were repeated at least three times.

Transwell invasion and migration assays. MGC-803 and MKN-45 cells were seeded in a 6-well plate (0.5x10⁶ cells/well) and transfected with 100 nM si-lncRNA-ATB or si-NC using Lipofectamine 2000 according to the manufacturer’s instructions. Following 48 h incubation at 37°C, the transfected cells were resuspended in serum-free DMEM and added in the upper Transwell chamber with a Matrigel coated membrane. For the migration assay, cells were seeded into the upper chamber without Matrigel. The bottom chamber was filled with 400 µl DMEM containing 20% FBS. Cells were incubated for 48 h at 37°C. Non-invasive cells were washed off the upper surface with a wet cotton swab, and the cells that passed to the lower surface were fixed in 4% paraformaldehyde at room temperature for 20 min and then stained with 0.5% crystal violet solution at room temperature overnight. Images of the invaded cells were captured using an Eclipse Ti-S1 SM inverted microscope (Nikon Corporation) at x10 magnification. Experiments were repeated at least three times.

Wound-healing assay. The migratory ability of GC cells was examined by wound-healing assay. At 48 h post-siRNA transfection, MGC-803 and MKN-45 were seeded in a 6-well plate (0.5x10⁶ cells/well). The cells were allowed to reach 90% confluence, after which a scratch was made through the center of each well using the 200 µl sterile pipette tip. The scratch was observed and imaged at 0, 24 and 48 h following the scratch using an Eclipse Ti-S1 SM inverted microscope (Nikon Corporation) with x10 magnification. Experiments were repeated at least three times.
**Western blot analysis.** Cellular proteins of transfected MGC-803 and MKN-45 cells were lysed on ice with radioimmunoprecipitation assay lysis buffer (BioTeke Corporation, Beijing, China) according to the manufacturer’s instructions. The concentration of protein was detected using a NanoDrop 2000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc., Pittsburgh, PA, USA). Equal amounts of protein extracts (20 µg/lane) were separated by 8% SDS-PAGE and transferred electrochemically to a polyvinylidene difluoride membrane (EMD Millipore, Billerica, MA, USA) using the Bio-Rad Semi-dry Transfer System (Bio-Rad Laboratories, Inc.). Membranes were blocked with 5% milk in PBS for 2 h at room temperature and probed with specific primary antibodies (1:1,000) against β-actin (cat. no. ab8227), vimentin (cat. no. ab45939), N-cadherin (cat. no. ab18203) and c-Myc (cat. no. ab1917) (all from Abcam, Cambridge UK), at 4°C overnight. Following 3 washes with PBS (5 min each), IRDye 650-conjugated goat anti-mouse (cat. no. 926-32210) immunoglobulin G secondary antibodies (1:200; LI-COR Biosciences, Lincoln, NE, USA) were added and incubated for 1 h in the dark at room temperature. Membranes were washed with PBS and bands were detected in a dark room using a Fluorescence Odyssey Imaging System (LI-COR Biosciences).

**Statistical analysis.** Analysis of the correlation between patient clinicopathological characteristics and lncRNA-ATB expression was performed using SPSS 22.0 software (IBM Corp., Armonk, NY, USA). The remaining data analysis was performed by GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). Comparison between two groups was performed using a Student’s t-test. Chi-square test was used for analyzing the correlation between lncRNA-ATB expression and clinicopathological features of the GC samples. Data was presented as the mean ± standard deviation. All of the P-values were two-tailed, and P<0.05 was considered to indicate a statistically significant difference.

**Results**

**lncRNA-ATB is overexpressed in GC tissues and cell lines.** The expression levels of lncRNA-ATB in 40 pairs of gastric tissues were measured by RT-qPCR. A total of 40 ratios value were obtained from 40 pairs of tissues, and the average value was 4.37. The 40 pairs were divided into a high-expression group (n=20; ratio >4.37) and a low-expression group (n=20; ratio <4.37) according to the average ratio value (average ratio=4.37; Fig. 1A). IncRNA-ATB expression was significantly higher in GC tumor tissues compared with expression in the adjacent non-tumor tissues (P<0.001; Fig. 1B). In addition, IncRNA-ATB expression was significantly higher in GC tissues from patients with distant metastasis (P<0.01; Fig. 1C), whereas IncRNA-ATB expression was not significantly correlated with lymph node metastasis (P>0.05; Fig. 1D). The expression of IncRNA-ATB was also examined in different GC cell lines and the GES-1 normal gastric cell line. The results demonstrated that IncRNA-ATB expression was higher in the GC cell lines compared with expression in GES-1 (Fig. 1E).

**Correlation between lncRNA-ATB expression and clinicopathological characteristics in patients with GC.** High lncRNA-ATB expression levels were positively correlated with invasion depth (P=0.003), distant metastasis (P=0.008) and tumor-node-metastasis (TNM) stage (P=0.001), compared with the low-expression group (Table I). However, no significant correlation was identified between the lncRNA-ATB expression and lymph node metastasis, distant metastasis, patient age and sex (P>0.05). Therefore, it was concluded that the overexpression of lncRNA-ATB may be associated with GC progression.

**lncRNA-ATB-knockdown suppresses cellular proliferation.** RT-qPCR results indicated that the level of lncRNA-ATB expression was significantly reduced in GC cells transfected with si-lncRNA-ATB compared with cells transfected with si-NC (P<0.01; Fig. 2A), which indicated that si-lncRNA-ATB could be used in further *in vitro* experiments. CCK-8 assay results demonstrated that cellular proliferation was significantly

### Table I. Correlation between lncRNA-ATB expression level and clinicopathological features in patients with gastric cancer.

<table>
<thead>
<tr>
<th>Clinical characteristics</th>
<th>n</th>
<th>Low</th>
<th>High</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;60</td>
<td>18</td>
<td>10</td>
<td>8</td>
<td>0.751</td>
</tr>
<tr>
<td>&lt;60</td>
<td>22</td>
<td>10</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td>0.514</td>
</tr>
<tr>
<td>Male</td>
<td>25</td>
<td>14</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>15</td>
<td>6</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Invasion depth</td>
<td></td>
<td></td>
<td></td>
<td>0.003</td>
</tr>
<tr>
<td>T1</td>
<td>4</td>
<td>3</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>T2</td>
<td>11</td>
<td>8</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>12</td>
<td>8</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>13</td>
<td>1</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
<td></td>
<td>0.070</td>
</tr>
<tr>
<td>0</td>
<td>16</td>
<td>12</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>13</td>
<td>4</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>7</td>
<td>3</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>4</td>
<td>1</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Metastasis</td>
<td></td>
<td></td>
<td></td>
<td>0.008</td>
</tr>
<tr>
<td>Yes</td>
<td>7</td>
<td>0</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>33</td>
<td>20</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
<td></td>
<td>0.001</td>
</tr>
<tr>
<td>I</td>
<td>13</td>
<td>11</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>12</td>
<td>7</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>8</td>
<td>2</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>7</td>
<td>0</td>
<td>7</td>
<td></td>
</tr>
</tbody>
</table>

lncRNA-ATB, long noncoding RNA-activated by transforming growth factor-β; TNM, tumor-node-metastasis.
suppressed in MGC-803 and MKN-45 cells transfected with si-lncRNA-ATB compared with si-NC transfected cells (P<0.01; Fig. 2B). The EdU assay also demonstrated reduced proliferative ability in MGC-803 cells (Fig. 2C) and in MKN-45 cells (Fig. 2D) transfected with si-lncRNA-ATB. Western blotting revealed that the expression of c-Myc, an indicator of cell proliferation, was notably reduced in the si-lncRNA-ATB group compared with the si-NC group (Fig. 2E).

**lncRNA-ATB-knockdown reduces the invasion and migration ability of GC cells.** In the wound healing assays, the migratory ability of both the MGC-803 cells (Fig. 3A) and the MKN-45 (Fig. 3B) cells transfected with si-lncRNA-ATB was notably reduced compared with the control si-NC transfected cells. To further examine the effects on cell migration and invasion, Transwell assays were performed. Knockdown of lncRNA-ATB resulted in fewer cells migrating through the chambers in both MGC-803 and MKN-45 cells (Fig. 3C). Similar results were obtained with Matrigel invasion assays (Fig. 3D). As lncRNA-ATB is a TGF-β-induced lncRNA, the effects of lncRNA-ATB on the EMT process were analyzed. It was demonstrated that the silencing of lncRNA-ATB resulted in the downregulated protein expression of the mesenchymal markers N-cadherin and vimentin (Fig. 3E).
Figure 2. lncRNA-ATB-knockdown suppresses cellular proliferation. (A) Relative lncRNA-ATB expression of lncRNA-ATB in MGC803 and MKN-45 gastric cancer cells transfected with si-lncRNA-ATB compared with si-NC transfected cells. (B) Cell Counting Kit-8 was used to examine cell viability at 48 h post-transfection in both MGC-803 and MKN-45 cells. (C and D) EdU incorporation assay was performed to further examine cell proliferation at 48 h post-transfection in (C) MGC-803 and (D) MKN-45 cells; red-labeled cells indicate the cells undergoing the proliferation process; magnification, x20. (E) Western blot analysis for the expression of c-Myc in MGC-803 and MKN-45 cells. Data are presented as the mean ± standard deviation; data are representative of three independent experiments. **P<0.01. lncRNA-ATB, long noncoding RNA-activated by transforming growth factor-β; NC, negative control; OD, optical density; siRNA, small interfering RNA.

Figure 3. lncRNA-ATB-knockdown reduces the invasion and migration ability of GC cells. (A and B) Wound healing assays demonstrated the reduced migration ability in (A) MGC-803 and (B) MKN-45 cells treated with si-lncRNA-ATB compared with si-NC control treated cells. (C) Cell migration was measured by Transwell assays with normal chambers; representative images were presented. (D) Cell invasion ability was measured by Transwell assays with Matrigel-coated chambers; representative images were presented. (C and D) Magnification, x10. (E) Western blot analysis demonstrated reduced protein expression levels of N-cadherin and vimentin in si-lncRNA-ATB-treated cells compared with si-NC control treated cells. lncRNA-ATB, long noncoding RNA-activated by transforming growth factor-β; NC, negative control; siRNA, small interfering RNA.
Discussion

The clinical outcome of patients with GC remains dismal with the 5-year survival rate as low as 25%, or less, despite the rapid progress in developing surgical techniques and molecular-targeted therapies (12). This may be attributed to the underlying highly complex molecular mechanisms, which involve multiple tumor suppressors and oncogenes, as well as some well-studied tumor-related signaling pathways (13). Therefore, it is essential to identify reliable molecular biomarkers of GC to improve the early diagnosis and overall survival rate. In addition, it may also provide additional clues to the development of individualized therapy.

Noncoding RNA was previously regarded as transcriptional ‘noise’ in the conventional opinion of gene regulation (14); however, an increasing number of studies have demonstrated their regulatory potential in a range of physiological and pathological processes (15). IncRNA-ATB was originally reported as a novel TGF-β-induced IncRNA that was highly overexpressed in HCC. IncRNA-ATB competitively binds to members of the miR-200 miRNA family, which results in the upregulated expression of ZEB1 and ZEB2 mRNA and protein, thus inducing EMT (6). Notably, knock down IncRNA-ATB expression was revealed to sufficiently abolish TGF-β-induced EMT in HCC cells, even with the involvement of many other TGF-β-induced EMT drivers, such as Snail, Twist and Slug (6,16). These results indicated an essential role of IncRNA-ATB in EMT regulation. Upregulated IncRNA-ATB expression levels were also demonstrated in GC (7) renal cell carcinoma (8), colorectal cancer (9) as well as breast cancer (10) tissues compared with the levels of expression in the paired normal tissues. Survival analysis also indicated the inverse relationship between IncRNA-ATB expression and cancer prognosis (17). However, IncRNA-ATB expression was reported to be decreased in pancreatic cancer tissues compared with the adjacent normal tissues, which suggested the role of IncRNA-ATB in tumor progression may be pro-tumorigenic or tumor suppressive (18). Interestingly, the similar duality of TGF-β signaling was also observed in the pancreatic ductal adenocarcinoma (19).

In the present study, IncRNA-ATB expression levels in GC tissues and GC cell lines were significantly higher compared with adjacent normal tissues and normal gastric mucosal cells. These results were consistent with a previous study (7). In addition, patients with distant metastasis exhibited high expression of IncRNA-ATB. Further correlational analysis with the clinicopathological features indicated that higher IncRNA-ATB expression was correlated with increased invasion depth, more distant metastasis and advanced TNM stage. However, a previous study reported no significant association between high IncRNA-ATB expression and depth of tumor invasion, distant metastasis or clinical stage (7). This contradiction may be due to differences in the high and low expression ratio groupings; analysis with a larger sample size is necessary to further investigate this.

The present study also performed in vitro experiments to investigate the role of IncRNA-ATB in GC cellular processes. As the MGC-803 and MKN-45 cell lines exhibited the highest expression of IncRNA-ATB, they were selected for in vitro experiments. The results indicated that the knockdown of IncRNA-ATB expression significantly suppressed the proliferation, migration and invasion abilities of GC cell lines. In addition, reduced expression levels of mesenchymal markers N-cadherin and vimentin were observed in cells with knocked-down IncRNA-ATB expression. These data suggested that the regulatory role of IncRNA-ATB in GC progression was fulfilled partially through the induction of EMT. However, the underlying regulatory mechanism requires further clarification.

In conclusion, the present study reported that the higher expression of IncRNA-ATB were positively correlated with invasion depth, distant metastasis and advanced TNM stage. In addition, it was demonstrated that knocking down IncRNA-ATB expression reduced the proliferation, migration and invasion ability of GC cell lines. These results suggested the potential role of IncRNA-ATB in clinical outcome prediction and molecular-targeted therapy in GC.

Acknowledgements

We would like to thank the contributions of all authors who participated in this study. This study was supported by the National Natural Science Foundation of China (grant no. 81572731).

References